Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib plus Gemcitabine in Pancreatic Cancer
NCT01373164Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2011
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of galunisertib in pancreatic cancer (PC), metastatic cancer, sponsored by Eli Lilly and Company. Started Jun 2011; status: completed.
02
Drugs
galunisertib
03
Conditions
pancreatic cancer (PC)metastatic cancer
Beyond the preview
Go deeper on NCT01373164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01373164.